공시 • Mar 23
Sunny Pharmtech Inc., Annual General Meeting, Jun 26, 2026 Sunny Pharmtech Inc., Annual General Meeting, Jun 26, 2026. Location: 4 floor building. o no,255, lung yuan 1st rd., longtan district, taoyuan city Taiwan New Risk • Mar 02
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$153m free cash flow). Earnings have declined by 2.5% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Share price has been volatile over the past 3 months (7.9% average weekly change). Market cap is less than US$100m (NT$2.75b market cap, or US$87.3m). New Risk • Jan 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$153m free cash flow). Earnings have declined by 2.5% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Market cap is less than US$100m (NT$2.53b market cap, or US$80.1m). Reported Earnings • Apr 27
Full year 2024 earnings released: NT$1.05 loss per share (vs NT$0.44 loss in FY 2023) Full year 2024 results: NT$1.05 loss per share (further deteriorated from NT$0.44 loss in FY 2023). Revenue: NT$418.0m (down 2.5% from FY 2023). Net loss: NT$156.0m (loss widened 146% from FY 2023). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. New Risk • Apr 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$100m (NT$2.13b market cap, or US$64.6m). 공시 • Mar 28
Sunny Pharmtech Inc., Annual General Meeting, Jun 16, 2025 Sunny Pharmtech Inc., Annual General Meeting, Jun 16, 2025. Location: 4 floor building. o no,255, lung yuan 1st rd., longtan district, taoyuan city Taiwan New Risk • Mar 02
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$112m free cash flow). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (NT$3.05b market cap, or US$92.6m). New Risk • Nov 28
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: NT$3.25b (US$99.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$112m free cash flow). Minor Risk Market cap is less than US$100m (NT$3.25b market cap, or US$99.7m). New Risk • Aug 18
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$112m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$112m free cash flow). Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Shareholders have been diluted in the past year (7.2% increase in shares outstanding). New Risk • Jul 31
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (7.2% increase in shares outstanding). Reported Earnings • Apr 18
Full year 2023 earnings released: NT$0.44 loss per share (vs NT$1.23 loss in FY 2022) Full year 2023 results: NT$0.44 loss per share (improved from NT$1.23 loss in FY 2022). Revenue: NT$428.8m (up 19% from FY 2022). Net loss: NT$63.3m (loss narrowed 63% from FY 2022). 공시 • Apr 04
Sunny Pharmtech Inc., Annual General Meeting, Jun 27, 2024 Sunny Pharmtech Inc., Annual General Meeting, Jun 27, 2024. New Risk • Mar 01
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (7.2% increase in shares outstanding). New Risk • Oct 30
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 7.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.7% average weekly change). Minor Risk Shareholders have been diluted in the past year (7.2% increase in shares outstanding). New Risk • Sep 11
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.4% average weekly change). Shareholders have been diluted in the past year (7.2% increase in shares outstanding). Reported Earnings • Aug 15
First half 2023 earnings released: NT$0.38 loss per share (vs NT$0.77 loss in 1H 2022) First half 2023 results: NT$0.38 loss per share (improved from NT$0.77 loss in 1H 2022). Revenue: NT$177.4m (up 14% from 1H 2022). Net loss: NT$52.1m (loss narrowed 51% from 1H 2022). Reported Earnings • Apr 12
Full year 2022 earnings released: NT$1.23 loss per share (vs NT$1.31 loss in FY 2021) Full year 2022 results: NT$1.23 loss per share (improved from NT$1.31 loss in FY 2021). Revenue: NT$359.6m (up 49% from FY 2021). Net loss: NT$170.2m (loss narrowed 2.6% from FY 2021). Reported Earnings • Aug 15
First half 2022 earnings released: NT$0.77 loss per share (vs NT$0.76 loss in 1H 2021) First half 2022 results: NT$0.77 loss per share (down from NT$0.76 loss in 1H 2021). Revenue: NT$155.4m (up 27% from 1H 2021). Net loss: NT$106.4m (loss widened 7.5% from 1H 2021). 공시 • Apr 04
Sunny Pharmtech Inc., Annual General Meeting, Jun 30, 2022 Sunny Pharmtech Inc., Annual General Meeting, Jun 30, 2022.